Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Glycobiology|July 9, 2018
Biophysical analysis of sialic acid recognition by the complement regulator Factor HChristoph Q Schmidt, Agnes L Hipgrave Ederveen, Markus J Harder, et al.Transfusion|October 28, 2018
Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assayMarkus Anliker, Christoph Q Schmidt, Markus J Harder, et al.Frontiers in Immunology|August 6, 2019
Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH PatientsMarkus J Harder, Britta Höchsmann, Arthur Dopler, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2019
Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1Arthur Dopler, Leonie Guntau, Markus J Harder, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 9, 2015
Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement RegulationMarkus J Harder, Markus Anliker, Britta Höchsmann, et al.The Journal of Biological Chemistry|September 2, 2015
Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1Nicholas T Y Lim, Markus J Harder, Alexander T Kennedy, et al.Blood|December 29, 2016
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activationMarkus J Harder, Nadine Kuhn, Hubert Schrezenmeier, et al.Immunobiology|January 22, 2016
Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patientsChristoph Q Schmidt, Markus J Harder, Eva-Maria Nichols, et al.Pageof 1